B7-H6/NKp30 Axis in Melanoma: Immune Surveillance, Tumor Escape, and Therapeutic Targeting
Preprint
- 29 April 2026
- preprint
- Published by MDPI AG in Preprints.org
Abstract
Melanoma treatment has been transformed by immune checkpoint blockade, yet many patients still experience primary resistance, limited durability of response, or acquired resistance. These limitations underscore the need for additional targets that reflect melanoma biology while enabling new therapeutic strategies. The B7-H6/NKp30 axis has gained attention as a link between tumor cell stress, immune recognition, and therapy-related adaptation. B7-H6 (NCR3LG1), an inducible ligand for NKp30, has been detected in melanoma cell lines and tumor specimens, and soluble B7-H6 has been identified in a subset of patients. Membrane-bound B7-H6 may support NK-cell activation, whereas ligand shedding and accumulation of soluble B7-H6 may reduce effective antitumor recognition and promote immune evasion. Emerging evidence further suggests that B7-H6 expression may be linked to tumor-intrinsic programs relevant to melanoma cell survival, migration, and adaptation to therapeutic stress. In this review, we examine the role of the B7-H6/NKp30 axis in immune surveillance, tumor escape, biomarker development, and therapeutic targeting, and discuss its translational potential in melanoma.Keywords
All Related Versions
- Version 1, 2026-04-29, Preprints
- Published version: Biomolecules, 16 (6), 862.
This publication has 46 references indexed in Scilit:
- Tumor Glycosylation: A Main Player in the Modulation of Immune ResponsesEuropean Journal of Immunology, 2025
- Efficient killing of tumor cells by CAR-T cells requires greater number of engaged CARs than TCRsJournal of Biological Chemistry, 2021
- Engineering a natural ligand-based CAR: directed evolution of the stress-receptor NKp30Cancer Immunology, Immunotherapy, 2021
- Advanced MelanomaHematology/Oncology Clinics of North America, 2021
- The integrated stress response promotes B7H6 expressionJournal of Molecular Medicine, 2019
- A Cancer Cell Program Promotes T Cell Exclusion and Resistance to Checkpoint BlockadeCell, 2018
- Characterization of B7H6, an endogenous ligand for the NK cell activating receptor NKp30, reveals the identity of two different soluble isoforms during normal human pregnancyImmunobiology, 2018
- HLA class I downregulation is associated with enhanced NK‐cell killing of melanoma cells with acquired drug resistance to BRAF inhibitorsEuropean Journal of Immunology, 2015
- B7-H6/NKp30 interaction: a mechanism of alerting NK cells against tumorsCellular and Molecular Life Sciences, 2011
- Down-Regulation of HLA Class I Antigen-Processing Molecules in Malignant MelanomaThe American Journal of Pathology, 1999